Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
McKesson
AstraZeneca
Teva
Farmers Insurance
Argus Health
Colorcon
McKinsey
Cerilliant

Generated: February 24, 2018

DrugPatentWatch Database Preview

TWINJECT 0.3 Drug Profile

« Back to Dashboard

Which patents cover Twinject 0.3, and when can generic versions of Twinject 0.3 launch?

Twinject 0.3 is a drug marketed by Impax Labs Inc and is included in one NDA. There are two patents protecting this drug.

This drug has forty-three patent family members in fifteen countries.

The generic ingredient in TWINJECT 0.3 is epinephrine. There are nineteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

US Patents and Regulatory Information for TWINJECT 0.3

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc TWINJECT 0.3 epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-001 May 30, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Impax Labs Inc TWINJECT 0.3 epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-001 May 30, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for TWINJECT 0.3

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,905,352 Kits containing medicine injection devices and containers ➤ Try a Free Trial
8,187,224 Methods performed by medicine injection apparatuses ➤ Try a Free Trial
7,927,303 Medicine injection devices and methods ➤ Try a Free Trial
7,931,618 Apparatuses and methods for injecting medicines to a desired depth ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for TWINJECT 0.3

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Fish and Richardson
McKinsey
Cerilliant
QuintilesIMS
Chinese Patent Office
Medtronic
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot